Although the present study shows that androgen receptor–non-specific (NS) peptides—particularly when combined—reduce prostate cancer cell viability, the absence of detectable effects on androgen receptor or PSA expression highlights mechanistic uncertainties. This evidence concerns the gene AR and prostate cancer.